Adjunctive Cilostazol in Patients With High Residual Platelet Reactivity After Drug-Eluting Stent Implantation: A...

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Dual antiplatelet therapy (DAPT) is standard after coronary stenting but may not fully inhibit platelet activity.
• High residual platelet reactivity (HRPR) persists in a significant portion of patients, increasing vascular occlusion risks.
• Cilostazol is being investigated as an adjunct to DAPT to enhance platelet inhibition.

Purpose of the Study:

• To evaluate the efficacy of adding cilostazol to DAPT in reducing HRPR.
• To compare platelet inhibition between standard DAPT and triple therapy (TAPT) with cilostazol.

Main Methods:

• A randomized, open-label study involving 148 patients screened for HRPR (defined as P2Y12 reaction units > 240).
• Patients with HRPR were randomized to receive either DAPT or TAPT (DAPT + cilostazol 100 mg twice daily).
• Platelet reactivity was assessed using VerifyNow P2Y12 assay, light transmittance aggregometry (LTA), and Multiplate electrode analyzer (MEA).

Main Results:

• HRPR was identified in 43.2% of screened patients.
• The TAPT group showed a significantly lower incidence of HRPR at 30 days compared to the DAPT group across all three assays (VerifyNow, LTA, MEA).
• TAPT demonstrated a significantly greater reduction in platelet activity compared to DAPT, as measured by VerifyNow and LTA.

Conclusions:

• Cilostazol, when added to DAPT, effectively reduces HRPR and platelet activity in patients post-coronary stenting.
• The findings suggest TAPT may offer superior platelet inhibition compared to standard DAPT.
• Further large-scale randomized trials are needed to confirm if these laboratory improvements translate to better clinical outcomes.